VANDETANIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24BrFN4O2
Molecular Weight	475.354
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of VANDETANIB

Structure Search

SMILES

COC1=CC2=C(C=C1OCC3CCN(C)CC3)N=CN=C2NC4=CC=C(Br)C=C4F

InChI

InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N

InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

HIDE SMILES / InChI

Molecular Formula	C22H24BrFN4O2
Molecular Weight	475.354
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:02:00 UTC 2023` Edited by `admin` on `Fri Dec 15 16:02:00 UTC 2023`
Record UNII	YO460OQ37K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VANDETANIB

Official Name

English

GNF-PF-2188

Code

English

VANDETANIB [VANDF]

Common Name

English

VANDETANIB [MART.]

Common Name

English

NSC-744325

Code

English

CAPRELSA

Brand Name

English

vandetanib [INN]

Common Name

English

NSC-760766

Code

English

ZD6474

Code

English

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

Systematic Name

English

VANDETANIB [USAN]

Common Name

English

VANDETANIB [JAN]

Common Name

English

VANDETANIB [MI]

Common Name

English

VANDETANIB [ORANGE BOOK]

Common Name

English

4-QUINAZOLINAMINE, N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYL-4- PIPERIDINYL)METHOXY)-

Systematic Name

English

ZD-64

Code

English

ZACTIMA

Brand Name

English

ZD-6474

Code

English

Vandetanib [WHO-DD]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

CAPRELSA (AUTHORIZED: THYROID NEOPLASMS)

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

LIVERTOX

NBK548169

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

NDF-RT

N0000175605

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

NCI_THESAURUS

C1742

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

NCI_THESAURUS

C2167

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

EU-Orphan Drug

EU/3/05/344

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

WHO-ATC

L01XE12

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

NCI_THESAURUS

C93259

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

FDA ORPHAN DRUG

211005

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

WHO-VATC

QL01XE12

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

Code System Code Type Description

IUPHAR

5717

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

NDF-RT

N0000185503

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

P-Glycoprotein Inhibitors [MoA]

EVMPD

SUB29174

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

ChEMBL

CHEMBL24828

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

NSC

744325

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

USAN

SS-07

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

DRUG CENTRAL

4178

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

NDF-RT

N0000187061

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

Organic Cation Transporter 2 Inhibitors [MoA]

NCI_THESAURUS

C2737

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

CAS

443913-73-3

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

HSDB

8198

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

DAILYMED

YO460OQ37K

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

WIKIPEDIA

Vandetanib

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

NSC

760766

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

INN

8365

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

EPA CompTox

DTXSID1046681

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

MERCK INDEX

m11387

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

Merck Index

LACTMED

Vandetanib

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

DRUG BANK

DB05294

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

PUBCHEM

3081361

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

SMS_ID

100000090715

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

CHEBI

49960

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

FDA UNII

YO460OQ37K

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

RXCUI

1098413

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

RxNorm

MESH

C452423

Created by admin on Fri Dec 15 16:02:00 UTC 2023 , Edited by admin on Fri Dec 15 16:02:00 UTC 2023

PRIMARY

Related Record Type Details


					C1P36E2V4Q

EPHRIN TYPE-B RECEPTOR 2

TARGET -> INHIBITOR


					66DDF797LP

OATP-8

TRANSPORTER -> SUBSTRATE


					IHD25862WV

FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 1 (HUMAN)

METABOLIC ENZYME -> SUBSTRATE


					9971WH3C6O

FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)

METABOLIC ENZYME -> SUBSTRATE


					482M00274D

OCT-2

TRANSPORTER -> INHIBITOR


					798536Z7S0

VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2

TARGET -> INHIBITOR


					13U1W2G8EZ

EPHRIN TYPE-A RECEPTOR 3

TARGET -> INHIBITOR


					3855YJE5N8

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET M918T

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					SWY4QNB42K

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804L

TARGET -> INHIBITOR RESISTANT

Qualification:

IC50

Amount:


					YO460OQ37K

EXCRETED UNCHANGED

Comments:

Within a 21-day collection period after a single dose of 14C-vandetanib, approximately 69% was recovered with 44% in feces and 25% in urine.

Qualification:

FECAL

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR

Amount:


					YO460OQ37K

EXCRETED UNCHANGED

Comments:

Within a 21-day collection period after a single dose of 14C-vandetanib, approximately 69% was recovered with 44% in feces and 25% in urine.

Qualification:

URINE

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					S276B35HIP

EPHRIN TYPE-A RECEPTOR 8

TARGET -> INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					N3H2YMZ2NH

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804M

TARGET -> INHIBITOR RESISTANT

Qualification:

IC50

Amount:


					RO03J093CP

EPIDERMAL GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Related Record Type Details


					K3YT3PC74T

N-OXIDE VANDETANIB

METABOLITE INACTIVE -> PARENT

Qualification:

FECAL; PLASMA; URINE


					K4I43R5TNP

N-DESMETHYL VANDETANIB

METABOLITE ACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

FECAL; PLASMA; URINE

Related Record Type Details


					YO460OQ37K

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC